These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8794019)

  • 41. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
    Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
    J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic dendritic-cell vaccine for simian AIDS.
    Lu W; Wu X; Lu Y; Guo W; Andrieu JM
    Nat Med; 2003 Jan; 9(1):27-32. PubMed ID: 12496959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm.
    Nilsson C; Mäkitalo B; Thorstensson R; Norley S; Binninger-Schinzel D; Cranage M; Rud E; Biberfeld G; Putkonen P
    AIDS; 1998 Dec; 12(17):2261-70. PubMed ID: 9863867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus.
    Stahl-Hennig C; Dittmer U; Nisslein T; Petry H; Jurkiewicz E; Fuchs D; Wachter H; Mätz-Rensing K; Kuhn EM; Kaup FJ; Rud EW; Hunsmann G
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2969-81. PubMed ID: 9000087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'.
    Vaccine; 1995 Feb; 13(3):295-300. PubMed ID: 7631516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.
    Abel K; Rourke T; Lu D; Bost K; McChesney MB; Miller CJ
    J Infect Dis; 2004 Nov; 190(9):1697-705. PubMed ID: 15478078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
    Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
    J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines.
    Wyand MS
    AIDS Res Hum Retroviruses; 1992 Mar; 8(3):349-56. PubMed ID: 1571195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SIV infection of macaques: a model for AIDS vaccine development.
    Gardner MB
    Dev Biol Stand; 1990; 72():259-66. PubMed ID: 2178124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional analyses of natural killer cells in macaques infected with neurovirulent simian immunodeficiency virus.
    Shieh TM; Carter DL; Blosser RL; Mankowski JL; Zink MC; Clements JE
    J Neurovirol; 2001 Feb; 7(1):11-24. PubMed ID: 11519478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Schmitz JE; Kuroda MJ; Santra S; Sasseville VG; Simon MA; Lifton MA; Racz P; Tenner-Racz K; Dalesandro M; Scallon BJ; Ghrayeb J; Forman MA; Montefiori DC; Rieber EP; Letvin NL; Reimann KA
    Science; 1999 Feb; 283(5403):857-60. PubMed ID: 9933172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
    Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MHC-I non-restricted cytotoxic activity in Macaca sylvana experimentally inoculated with HIV2 and SIV/mac.
    Charaf B; Sanhadji K; Sekkat S; Farouqui B; Touraine JL; Benslimane A
    Thymus; 1993 Aug; 22(1):1-12. PubMed ID: 7905683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunization for long-term protection against AIDS using the macaque model.
    Kumar A; Narayan O
    Virology; 2001 Jun; 285(1):1-5. PubMed ID: 11414799
    [No Abstract]   [Full Text] [Related]  

  • 57. AIDS. Escape from the immune system.
    Walker BD; Goulder PJ
    Nature; 2000 Sep; 407(6802):313-4. PubMed ID: 11014174
    [No Abstract]   [Full Text] [Related]  

  • 58. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.
    Rose NF; Marx PA; Luckay A; Nixon DF; Moretto WJ; Donahoe SM; Montefiori D; Roberts A; Buonocore L; Rose JK
    Cell; 2001 Sep; 106(5):539-49. PubMed ID: 11551502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?
    Vogel TU; Friedrich TC; O'Connor DH; Rehrauer W; Dodds EJ; Hickman H; Hildebrand W; Sidney J; Sette A; Hughes A; Horton H; Vielhuber K; Rudersdorf R; De Souza IP; Reynolds MR; Allen TM; Wilson N; Watkins DI
    J Virol; 2002 Nov; 76(22):11623-36. PubMed ID: 12388723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-HIV adaptive immunity: determinants for viral persistence.
    Yamamoto H; Matano T
    Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.